Eric Ostertag, Poseida CEO (via website)

On the heels of sol­id tu­mor da­ta and with com­peti­tors surg­ing, Po­sei­da scraps au­tol­o­gous CAR-T in fa­vor of al­lo

Po­sei­da CEO Er­ic Os­tertag was not shy about the prospects he sees for au­tol­o­gous CAR-T ther­a­pies in the age of off-the-shelf al­ter­na­tives: They are “go­ing the way of the di­nosaur.”

His com­pa­ny is of­fi­cial­ly start­ing that piv­ot.

In its quar­ter­ly up­date, San Diego-based Po­sei­da an­nounced that it’s wind­ing down the P-BC­MA-101 au­tol­o­gous pro­gram, one of its for­mer leads, as part of a “planned strate­gic shift to al­lo­gene­ic BC­MA” — name­ly P-BC­MA-AL­LO1.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.